Germany Cardiovascular Drug Industry Outlook 2022 - 2026

See how Germany Cardiovascular Drug performed compared to key markets such as Italy and Canada.

Key Market Indicators

Sales of beta-blocking medicines in Germany will drop slightly to $793 million by 2026, down 0.2% annually on average. This follows a steady rise since 1991, when sales amounted to $815 million in 2021. Italy, Canada and Australia are the second, third and fourth-largest markets for beta-blocking drugs, respectively.

Germany Cardiovascular Drug Market Data and Forecasts

Germany Cardiovascular Drug : how will it grow in the coming years?

Forecast: Cardiovascular System Medicine Sales in Germany
Forecast: Cardiovascular System Medicine Sales in Germany
Forecast: Cardiac Glycosides Sales in Germany
Forecast: Cardiovascular System Medicine Sales in Germany
Forecast: Antiarrhythmic Medicine Sales in Germany
Forecast: Antiarrhythmic Medicine Sales in Germany
Forecast: Renin-Angiotensin System Medicine Sales in Germany
Forecast: Cardiovascular System Medicine Sales in Germany
Forecast: Calcium Channel Blocking Medicine Sales in Germany

Other Top Countries about Cardiovascular Drug